Company intelligence / Profile preview
RayzeBio
San Diego, California, United Statesrayzebio.com ↗
- Ownership
- Public · RYZB
- Development stage
- Other
01
Overview
Lead asset RYZ101 is in Phase 3 testing for GEP-NETs and earlier stage testing for SCLC. The company has multiple programs in development using Actinium-225, a powerful alpha-emitting radioisotope.
- Therapeutic areas
- Oncology
- Modalities
- Targeted radiopharmaceuticalsspecifically Actinium-225 (alpha-emitting radioisotope)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Relationships with Actinium-225 suppliers
Beyond the preview
Go deeper on RayzeBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RayzeBio.